Pages
- Home
- Processes
- Propellants
- Regulatory
- About Bespak
- Sustainability
- ESG Leadership
- Our ESG Strategy
- Reducing Our Climate Impact
- Enriching Our Communities
- Reports and Publications
- Our people
- Resources
- News
- Events
- Careers
- Contact Us
- Privacy Policy
- Cookies Policy
- Website Terms
- Bespak® Standard Terms and Conditions of Supply (UK)
- Code of Conduct
- Whistleblowing Policy
- Bespak® Standard Terms and Conditions of Purchase
- Modern Slavery Statement
- Tax Strategy
- Pre DDL 2025 exclusive event
Platforms
- Actuators and Dose Counters
- Dry Powder Inhalers
- Medical Check Valves
- Nasal Delivery
- pMDI Pressurised Metered Dose Inhalers
- Soft Mist Inhalers
- Valves
News
- Council celebrates world first green inhaler manufacturer during ‘Made in Cheshire’ visit
- Chiesi and Bespak partner to advance Carbon Minimal Inhaler production with UK manufacturing site
- Bespak Joins United Nations Global Compact for Sustainability
- Bespak receives approval for net-zero and near-term targets with SBTi
- Bespak advances progress on United Nations (UN) Sustainable Development Goals (SDGs)
- Bespak commits to net-zero and near-term targets with SBTi
- Bespak strengthens commitment to sustainability with the release of its inaugural ESG Update 2024
- Bespak achieves sustainability milestone with first life cycle assessment for pressurised Metered Dose Inhaler valve
- Resyca receives Medical Device Regulation Certificate from TÜV SÜD
- Bespak welcomes Sarah Russell MP to new climate-friendly inhaler production facility at Holmes Chapel site
- Bespak and OzUK further strengthen pressurised Metered Dose Inhaler product development partnership with low Global Warming Potential propellant capability enhancements
- Bespak and Orbia Fluor & Energy Materials unite to accelerate transition to climate-friendly inhalers
- Bespak announces closure of North Carolina site
- Bespak & H&T Presspart announce availability of GMP pilot line for low GWP pMDIs
- Bespak takes a seat on the Board at IPAC
- Bespak reaches key milestone in the expansion of its manufacturing capacity, with further expansion plans underway to meet global customer demand for climate friendly inhalers
- DevPro Biopharma and Bespak announce completion of early feasibility study for new ground-breaking albuterol inhaler
- Bespak and H&T Presspart enter into collaboration agreement to advance transition to low GWP propellants in pMDIs
- Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers
- Bespak confirms completion of inhaled and nasal drug delivery business separation from Recipharm to focus on the transition to low GWP pMDIs
- Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
- Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant
- Recipharm makes senior appointments as transition to low global warming potential propellants in pressurised Metered Dose Inhalers gains pace
- Honeywell And Recipharm To Speed Development Of Inhalers With A Near-Zero Global Warming Potential Propellant
- Stevanato Group collaborates with Resyca® to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products
- Recipharm Invests In Its Single Dose Nasal Platform Capabilities
- Recipharm offers services to enable switch to next generation pMDI propellants
Events
- RDD 2024
- CPHI Milan 2024
- DDL 2024
- Pharmapack 2025
- Exploring the Future of Inhalation Drug Delivery International Conference
- RDD Asia 2024
- The International Society of Aerosols in Medicine (ISAM) Congress 2025
- RDD Europe 2025
- SMI London 2025
- CPHI 2025
- DDL 2025
- London Climate Action Week
- DCAT Week 2026
- CPHI Milan 2026
- RDD 2026
- DDL 2026
- Nasal Formulation & Delivery Summit 2026
- SMI London 2026
- University of Parma - Exploring the Future of Inhalation Drug Delivery 2026
- BIO 2026
- ATS 2026
- RespireX 2026
- Webinar - Digital engineering for inhalers: Robust design optimisation of pMDI valves
Resources
- Simulating in vitro aerosolisation performance: A tool to support valve selection for suspension pMDI products
- Decarbonising the pMDI valve: Designing a low carbon valve for the next generation of pMDIs
- Accelerating the green transition: A digital-first approach to inhaler design
- From commitment to capability: What sustainability leadership really requires in the inhalation industry
- The physics of the switch: Optimising pMDI design for low carbon lung delivery
- Sustainability by design: How AI and cross-industry collaboration are reshaping inhaled and nasal drug-device development
- Regulatory foresight in the green transition: From compliance to competitive advantage
- Facility spotlight: Device design and development at King’s Lynn
- SASB Report (2025)
- Sustainability in inhalation: From global agreement to industry action
- Voices of Change: Alan Harris
- Special feature: Artificial Intelligence
- The 2025 recap: Commitment, collaboration and a clear vision for a greener future
- The transition in action: When innovation meets collaboration, even the sky isn't the limit
- Voices of Change: Louise Righton - A final breath, a global promise
- Mapping the product design space: A case study
- Computational modelling of metering chamber refill in pMDIs with current and next-generation propellants
- Championing sustainability in the inhalation industry
- Voices of Change: Nick Atkinson - A year of progress
- Net Zero Carbon roadmap
- UK-based capabilities in inhaled and nasal drug-device product development
- Scaling low carbon pMDI production without disrupting patient access
- The implementation of biodiversity footprinting: Examining supply chains
- Voices of Change: Chris Hirst
- Bespak at a glance: Expertise, innovation & sustainability
- Living and breathing the inhalation industry’s green transition
- Scaling capabilities in nasal drug delivery
- Championing a safe transition to low carbon inhalers
- Industry challenges in low carbon pMDI manufacturing
- Adapting valves for greener propellants
- Biodiversity Report 2025
- Shortening & decarbonising the inhalation supply chain
- Verification Report: Bespak Scope 3 Baseline Greenhouse Gas Emissions (2023)
- Sustainable foundations: embedding principles at every level
- New era, new rules: Steering the low carbon pMDI regulatory conversation
- Bespak ESG Update (2024)
- GRI Report (2024)
- Limited Assurance Report: Bespak Health and Safety Data (2024)
- Double Materiality Assessment (2024)
- SASB Report (2024)
- Limited Assurance Report: Bespak Scope 1–3 Greenhouse Gas Emissions (2024)
- Verification Report: Bespak Scope 1–2 Baseline Greenhouse Gas Emissions (2020)
- Preparing for the future of device contract manufacturing
- Development of albuterol sulfate pMDI using HFO-1234ze. Human factors engineering considerations
- Mapping the product design space: Understanding and controlling manufacturing variability in pMDIs
- Development of albuterol sulfate pMDI using HFO-1234ze. Formulation, container closure and actuator selection considerations
- The transition to low GWP propellants in pMDIs – Increasing your probability of success using a collaborative approach
- Picking up speed: The propellant transition accelerates
- pMDI valve (BK357) LCA certificate
- A shared goal: collaborating to bring low carbon pMDIs to market
- Q&A with Sarah Bunyan: Understanding and anticipating regulation in the pMDI space
- Semantics of sustainability: why we’re saying ‘low carbon’
- Creating a climate for change: Reflecting on a remarkable year of Bespak with Chris Hirst CEO
- Top five trends for DPI manufacturing in 2025 and beyond
- A new landscape for pMDIs
- Evaluating the impact on spray performance aspects of a user-independent unit dose nasal device
- Injection Moulding Academy
- Comparability of aerosol performance of salbutamol sulphate nebuliser solution delivered from Resyca® Pulmospray™ and pre-filled syringe inhaler (PFSI™)
- Ready to face the complexities of the green transition?
- Demystifying inhaled and nasal drug product development
- Interview with Bespak’s Louise Righton & Benedicta Bakpa
- Voices of Change: Louise Righton
- Voices of Change: Richard Turner
- Voices of Change: Simon Gardner
- Voices of Change: Nick Atkinson
- Adapting to new pressures: Leading the transition to climate-friendly pMDIs
- Manufacturing of pMDIs using propellant HFO-1234ze(E)
- Development of albuterol sulphate pMDI using a low-GWP propellant (HFA-152a)
- Development of beclomethasone dipropionate pMDI using a low-GWP propellant (HFO-1234ze)
- Using human factors studies to optimise nozzle geometry of a unit dose nasal spray
- Investigating the impact of device design and propellant choice on the aerosolisation of fluticasone propionate suspensions in HFA-152a & HFO-1234ze
- Trusted valves optimised for the new era
- Device contract manufacturing capabilities from design to commercial supply
- The New Bespak: Championing Sustainability with Chris Hirst
- BK640 Integrated Dose Counter (IDC)
- NasaDose®
- BK361 Easifill pMDI Valve
- BK357 valve platform
- Resyca® PFSI™ Soft Mist Inhaler (SMI) : A breath of innovation
- Resyca® Pulmospray™ Soft Mist Inhaler (SMI) : A breath of innovation
- NasaDose® - Intuitive by Design
- Medical check valves designed with quality and safety at the forefront
- Customisable dose counting actuators: helping patients breathe more easily
- NasaDose® unit dose nasal device
- Resyca® Pulmospray™ Soft Mist Inhaler (SMI): fast preparation and breath-synchronised delivery
- Resyca® PFSI™ Soft Mist Inhaler (SMI): Inhalation spray in a convenient device
- Resyca® Soft Nasal Spray Adaptor: low shear forces and optimal nasal coverage